MediPharm Labs Corp.
LABS.TO
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 31.23M | 32.31M | 32.98M | 31.85M | 30.88M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 31.23M | 32.31M | 32.98M | 31.85M | 30.88M |
| Cost of Revenue | 21.83M | 22.07M | 23.46M | 21.82M | 20.67M |
| Gross Profit | 9.39M | 10.24M | 9.52M | 10.03M | 10.21M |
| SG&A Expenses | 14.65M | 15.17M | 15.13M | 15.86M | 15.02M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 336.20K | 221.90K | 83.00K | 111.50K | 192.00K |
| Total Operating Expenses | 36.94M | 37.61M | 38.84M | 38.02M | 36.10M |
| Operating Income | -5.71M | -5.30M | -5.86M | -6.17M | -5.22M |
| Income Before Tax | -6.32M | -5.96M | -5.78M | -6.26M | -5.42M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.32 | -5.96 | -5.78 | -6.26 | -5.42 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.32M | -5.96M | -5.78M | -6.26M | -5.42M |
| EBIT | -5.71M | -5.30M | -5.86M | -6.17M | -5.22M |
| EBITDA | -4.57M | -4.14M | -4.61M | -4.85M | -3.66M |
| EPS Basic | -0.02 | -0.01 | -0.01 | -0.02 | -0.01 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.01 | -0.01 | -0.02 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.68B | 1.67B | 1.66B | 1.65B | 1.64B |
| Average Diluted Shares Outstanding | 1.68B | 1.67B | 1.66B | 1.65B | 1.64B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |